Precision Oncology: Three Small Steps Forward

Hannah C Wise; David B Solit

doi:10.1016/j.ccell.2019.05.009

Precision Oncology: Three Small Steps Forward

Cancer Cell. 2019 Jun 10;35(6):825-826. doi: 10.1016/j.ccell.2019.05.009.

Authors

Hannah C Wise¹, David B Solit²

Affiliations

¹ Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: solitd@mskcc.org.

Abstract

Only a subset of cancer patients currently benefit from personalized treatment approaches. Detection of actionable drug targets in cell-free DNA, more comprehensive molecular profiling integrating transcriptional analyses, and personalized combination regimens all hold promise in expanding the benefits of personalized oncology to larger numbers of cancer patients.

Publication types

Comment

MeSH terms

Humans
Neoplasms*
Patient Selection
Precision Medicine

Grants and funding

P30 CA008748/CA/NCI NIH HHS/United States